Elevance Health, Inc. vs Merck & Company, Inc. — Stock Comparison
Elevance Health, Inc. (ELV) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. scores ahead of Elevance Health, Inc. on Q·Score (6.9 vs 5.9 out of 10), led by Growth (6.2 vs 3.9) and Quality (7.7 vs 6.2). Elevance Health, Inc. scores higher on Sentiment, reflecting stronger analyst and market sentiment. Analyst consensus targets imply greater upside for MRK (+7.4%) than for ELV (+3.7%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
68% of 22 covering analysts have a positive rating.
⚠ earnings contracting 17% year-over-year.
High-quality business with 19% return on equity and 14% profit margins.
Analyst Consensus
Fundamentals
Frequently Asked Questions
ELV vs MRK: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 6.9/10 versus Elevance Health, Inc. (ELV) at 5.9/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: ELV or MRK?
Merck & Company, Inc. (MRK) scores higher on Growth (6.2/10 vs 3.9/10). Elevance Health, Inc. reports revenue growth (2.6% YoY) while Merck & Company, Inc. reports (4.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is ELV or MRK more attractively valued?
Merck & Company, Inc. (MRK) scores higher on Valuation (6.4/10 vs 5.9/10). ELV trades at 13.3× P/E versus MRK at 12.6×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about ELV vs MRK?
There are 21 analysts covering ELV with a consensus price target of $404.05, and 27 analysts covering MRK with a consensus target of $129.74. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: ELV or MRK?
Merck & Company, Inc. (MRK) scores higher on Quality (7.7/10 vs 6.2/10). Net profit margin: ELV at 2.6%, MRK at 13.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: ELV or MRK?
Merck & Company, Inc. (MRK) scores higher on Financial Health (7/10 vs 6.5/10). Market beta: ELV at 0.67, MRK at 0.20. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of ELV and MRK?
Elevance Health, Inc. (ELV) has a market capitalisation of $84.6B, while Merck & Company, Inc. (MRK) has a market cap of $298.4B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do ELV or MRK pay dividends?
ELV pays a dividend yield of 1.76%, while MRK pays a dividend yield of 2.83%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →